NON RARE IN EUROPE: Metabolic syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:411969
Who is this for?
Show terms as
View depth
51Active trials8Treatment centers

Where are you in your journey?

UniteRare data is compiled from authoritative primary sources (FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, NORD), then processed through automated and AI-assisted extraction pipelines.
Report missing data

What is NON RARE IN EUROPE: Metabolic syndrome?

Metabolic syndrome is a common condition where several health problems occur together, raising your risk of heart disease, stroke, and type 2 diabetes. It is not considered a rare disease in Europe, but it is tracked in medical databases because of its significant health impact. To be diagnosed with metabolic syndrome, you typically need to have at least three of the following five conditions at the same time: a large waistline (excess belly fat), high blood pressure, high blood sugar levels, high triglycerides (a type of fat in the blood), and low levels of HDL cholesterol (the "good" cholesterol). Each of these problems is harmful on its own, but when they cluster together, the risks multiply significantly. Metabolic syndrome develops gradually over time and is strongly linked to being overweight, physical inactivity, and insulin resistance — a condition where your body does not use insulin properly. Genetics also play a role, as the tendency to develop these metabolic problems can run in families. The condition is sometimes called Syndrome X, insulin resistance syndrome, or dysmetabolic syndrome. The good news is that metabolic syndrome is largely manageable and even reversible with lifestyle changes. Losing weight, eating a heart-healthy diet, exercising regularly, and quitting smoking can dramatically improve all the components of the syndrome. When lifestyle changes are not enough, doctors may prescribe medications to control blood pressure, blood sugar, and cholesterol levels individually. Early detection and consistent management are key to preventing serious complications like heart attacks and diabetes.

Key symptoms:

Large waistline or excess belly fatHigh blood pressureHigh blood sugar or prediabetesHigh triglyceride levels in the bloodLow HDL (good) cholesterol levelsFatigue and low energyIncreased thirst and frequent urinationBlurred visionSkin tagsDark patches of skin on the neck or armpits (acanthosis nigricans)Difficulty losing weightFeeling hungry often

Inheritance
Multifactorial
Caused by a mix of several genes and environmental factors
Age of Onset
Adult
Begins in adulthood (age 18 or older)
Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Sep 2026Impact of Lifestyle on Health Maintenance: A Randomized Controlled Trial

University of Zadar — NA

TrialNOT YET RECRUITING
Sep 2026Metabolic Obesity in Normal Weight (MONW): Diagnostic Markers Stud

Pomeranian Medical University Szczecin

TrialNOT YET RECRUITING
Apr 2026Development and Multicenter Validation of an AI-Based Remote Photoplethysmography (rPPG) Facial Scan for Multimodal Health Assessment

Tarumanagara University

TrialNOT YET RECRUITING
Apr 2026Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) — PHASE2

TrialNOT YET RECRUITING
Apr 2026Effect of Insulin Lowering on Lipogenesis

Columbia University — PHASE1

TrialRECRUITING
Apr 2026Emotional Eating, Sleep Quality, Mental State and Metabolic Syndrome

Abant Izzet Baysal University

TrialNOT YET RECRUITING
Apr 2026Assessing the Association Between H. Pylori Persistence and the Severity of Insulin Resistance in Patients With Metabolic Syndrome

Center of New Medical Technologies

TrialRECRUITING
Feb 2026Comparing a Healthy Beef-Centric Diet to a Healthy U.S.-Style Diet on Metabolic Health Outcomes in Pre-Diabetic Adults

National Cattlemen's Beef Association, a contractor to the Beef Checkoff — NA

TrialRECRUITING
Jan 2026SCUBE Proteins in Polycystic Ovary Syndrome (IPSOS)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS — NA

TrialNOT YET RECRUITING
Jan 2026Effectiveness and Implementation of a Community-based Health Coach-led Artificial Intelligence (AI)-Powered Digital Self-Regulation Program for Individuals With Metabolic Syndrome (MetS)

National University Health System, Singapore — NA

TrialRECRUITING

Data is compiled from FDA regulatory filings and ClinicalTrials.gov, then processed through automated extraction; event classifications and dates may occasionally be misclassified. Verify against the linked FDA filing or trial record before clinical decisions. Updated periodically.

Treatments

Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly

No FDA-approved treatments are currently listed for NON RARE IN EUROPE: Metabolic syndrome.

20 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

20 recruitingView all trials with filters →

Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest

Phase 31 trial
Tongmai Jiangtang Capsule for Cardiovascular Clinical Outcomes in High-Risk Metabolic Syndrome Patients
Phase 3
Enrolling by Invitation
· Sites: Guangzhou, Guangdong · Age: 65+ years
Phase 41 trial
Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome
Phase 4
Actively Recruiting
PI: Kuat Oshakbayev, professor (University Medical Center, Kazakhstan) · Sites: Astana, Astana · Age: 35–65 yrs
Phase 23 trials
Acupuncture or Metformin for Insulin Resistance in Women With PCOS
Phase 2
Actively Recruiting
PI: Elisabet Stener-Victorin, PhD (Karolinska Institutet) · Sites: Beijing; Stockholm · Age: 18–40 yrs
Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy
Phase 2
Actively Recruiting
PI: Maggie Abbassi, Prof. (Cairo University) · Sites: Cairo · Age: 18–65 yrs
Combined Oral Contraceptive Pill and Resistance Starch
Phase 2
Actively Recruiting
· Sites: Philadelphia, Pennsylvania · Age: 18–40 yrs
Phase 13 trials
Graded Insulin Suppression Test P&F
Phase 1
Actively Recruiting
PI: Joshua R Cook, MD, PhD (Columbia University) · Sites: New York, New York · Age: 18–65 yrs
Effect of Insulin Lowering on Lipogenesis
Phase 1
Actively Recruiting
PI: Joshua R Cook, MD, PhD (Columbia University) · Sites: New York, New York · Age: 18–65 yrs
Diazoxide Suppression Test P&F Study
Phase 1
Actively Recruiting
PI: Joshua R Cook, MD, PhD (Columbia University) · Sites: New York, New York · Age: 18–65 yrs
N/A2 trials
The Impact of Exercise Methods on Human Body Functions and Metabolism
N/A
Actively Recruiting
PI: xiaomeng liu (Zhoukou Normal University) · Sites: Zhoukou, Henan · Age: 18–65 yrs
To Compare the Effects of Herbal Medicines With Traditional Allopathic Medicines in Cases of Patients With Metabolic Syndrome
N/A
Actively Recruiting
· Sites: Karachi, Sindh · Age: 35–65 yrs
Other10 trials
Adaptive Immune Response in Visceral and Subcutaneous Fat: Role in Human Insulin Resistance
Enrolling by Invitation
PI: Tracey McLaughlin, MD (Stanford University) · Sites: Stanford, California · Age: 30–65 yrs
BNP in Pediatric Metabolic Syndrome
Actively Recruiting
· Sites: Pavia, pavia · Age: 13–18 yrs
Blood Specimen Collection For Laboratory Assay Research
Actively Recruiting
PI: Nitin Vaswani, MD (Principal Investigator) · Sites: San Francisco, California · Age: 18+ years
Effect of Bariatric Surgery Versus Medical Therapy on Metabolic Syndrome
Actively Recruiting
· Sites: Chongqing, Chongqing Municipality · Age: 18–65 yrs
The Role of Ectopic Fat and Heart Attack Risk in HIV
Actively Recruiting
· Sites: Liverpool · Age: 40+ years
Assessing the Association Between H. Pylori Persistence and the Severity of Insulin Resistance in Patients With Metabolic Syndrome
Actively Recruiting
· Sites: Novosibirsk, Novosibirsk Oblast · Age: 18–65 yrs
Evaluation of MG53 (TRIM72) Levels in Women With Polycystic Ovary Syndrome: An Observational Study
Enrolling by Invitation
PI: Enes S Coşkun, M.D. (University of Health Sciences, Gaziosmanpaşa Train) · Sites: Gaziosmanpaşa, Istanbul · Age: 18–45 yrs
Genetic Susceptibility to Predict Weight Loss After Bariatric Surgery
Actively Recruiting
PI: Albert Lecube Torelló, PhD (Institut de Recerca Biomèdica de Lleida) · Sites: Lleida, Leida · Age: 18–65 yrs
Breath Mass Spectrometry in Metabolic Syndrome and Metabolically Healthy Obesity
Actively Recruiting
· Sites: Moscow · Age: 18+ years
Exercise and Carotid Artery Function in Metabolic Syndrome
Actively Recruiting
PI: William Schrage, PhD (University of Wisconsin, Madison) · Sites: Madison, Wisconsin · Age: 18–40 yrs

Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)

No specialists are currently listed for NON RARE IN EUROPE: Metabolic syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers

Source: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months

🏨 Children's

Children's Hospital Colorado Rare Disease Program

Children's Hospital Colorado

📍 Aurora, CO

👤 Boston Children's Hospital Rare Disease Program

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Boston Children's Hospital Rare Disease Program

Boston Children's Hospital

📍 Boston, MA

👤 Boston Children's Hospital Rare Disease Program

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

🏨 Children's

Ann & Robert H. Lurie Children's Hospital Genetics

Lurie Children's Hospital

📍 Chicago, IL

👤 Boston Children's Hospital Rare Disease Program

🏥 NORD

Cincinnati Children's Hospital Medical Center

Cincinnati Children's

📍 Cincinnati, OH

👤 Boston Children's Hospital Rare Disease Program

🏨 Children's

Nationwide Children's Hospital Rare Disease Center

Nationwide Children's Hospital

📍 Columbus, OH

👤 Boston Children's Hospital Rare Disease Program

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

Travel Grants

No travel grants are currently matched to NON RARE IN EUROPE: Metabolic syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open NON RARE IN EUROPE: Metabolic syndromeForum →

No community posts yet. Be the first to share your experience with NON RARE IN EUROPE: Metabolic syndrome.

Start the conversation →

Latest news about NON RARE IN EUROPE: Metabolic syndrome

Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC

No recent news articles for NON RARE IN EUROPE: Metabolic syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Which specific components of metabolic syndrome do I have, and which are the most concerning for me?,What is my current risk level for developing heart disease or type 2 diabetes?,What specific dietary changes would benefit me the most?,How much weight loss would I need to achieve to significantly improve my condition?,Do I need medications right now, or can I try lifestyle changes first?,How often should I have my blood pressure, blood sugar, and cholesterol levels checked?,Should my family members be screened for metabolic syndrome as well?

Common questions about NON RARE IN EUROPE: Metabolic syndrome

What is NON RARE IN EUROPE: Metabolic syndrome?

Metabolic syndrome is a common condition where several health problems occur together, raising your risk of heart disease, stroke, and type 2 diabetes. It is not considered a rare disease in Europe, but it is tracked in medical databases because of its significant health impact. To be diagnosed with metabolic syndrome, you typically need to have at least three of the following five conditions at the same time: a large waistline (excess belly fat), high blood pressure, high blood sugar levels, high triglycerides (a type of fat in the blood), and low levels of HDL cholesterol (the "good" cholest

How is NON RARE IN EUROPE: Metabolic syndrome inherited?

NON RARE IN EUROPE: Metabolic syndrome follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does NON RARE IN EUROPE: Metabolic syndrome typically begin?

Typical onset of NON RARE IN EUROPE: Metabolic syndrome is adult. Age of onset can vary across affected individuals.

Are there clinical trials for NON RARE IN EUROPE: Metabolic syndrome?

Yes — 20 recruiting clinical trials are currently listed for NON RARE IN EUROPE: Metabolic syndrome on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Frequently asked questions about NON RARE IN EUROPE: Metabolic syndrome

Auto-generated from canonical disease facts (Orphanet, OMIM, ClinicalTrials.gov, openFDA, NPPES). Not a substitute for clinical guidance.

  1. What is NON RARE IN EUROPE: Metabolic syndrome?

    NON RARE IN EUROPE: Metabolic syndrome is a rare disease catalogued in international rare-disease ontologies (Orphanet ORPHA:411969). It is typically inherited as multifactorial. Age of onset is generally adult. For verified primary sources, see the UniteRare NON RARE IN EUROPE: Metabolic syndrome page.

  2. How is NON RARE IN EUROPE: Metabolic syndrome inherited?

    NON RARE IN EUROPE: Metabolic syndrome follows multifactorial inheritance. Genetic counseling is recommended for affected families to understand recurrence risk in offspring and the likelihood of unaffected siblings being carriers. Variants in the underlying gene(s) may be identified via clinical genetic testing.

  3. Are there FDA-approved treatments for NON RARE IN EUROPE: Metabolic syndrome?

    Approved treatments for NON RARE IN EUROPE: Metabolic syndrome are tracked from openFDA and DailyMed primary sources. Many rare diseases have no specific FDA-approved therapy; for those, supportive care and management of complications form the basis of clinical care. Orphan-drug-designation status is noted where applicable.

  4. Are there clinical trials recruiting for NON RARE IN EUROPE: Metabolic syndrome?

    UniteRare currently lists 20 clinical trials relevant to NON RARE IN EUROPE: Metabolic syndrome sourced from ClinicalTrials.gov. Each trial entry includes recruitment status, eligibility criteria summary, principal-investigator information, and study locations. Patients should discuss eligibility with their healthcare provider before enrolling.

  5. How do I find a specialist for NON RARE IN EUROPE: Metabolic syndrome?

    Verified NON RARE IN EUROPE: Metabolic syndrome specialists are identified through ClinicalTrials.gov principal-investigator records, peer-reviewed publication authorship (via PubMed), and the NPPES NPI registry. NORD-designated Centers of Excellence and NIH-affiliated rare-disease clinics are also tracked. UniteRare's specialist directory is updated continuously as new evidence becomes available.

See full NON RARE IN EUROPE: Metabolic syndrome page for complete clinical details, sources, and verified-specialist listings.

Cite this page

Select a citation format above to view and copy.